跳至主要内容
临床试验/CTIS2023-504511-32-00
CTIS2023-504511-32-00进行中(未招募)1 期

ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transcatheter aortic valve implantation for aortic stenosis: the ATLANTIS Protamine study. - APHP211046

Assistance Publique Hopitaux De Paris0 个研究点目标入组 940 人开始时间: 2023年7月17日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
940

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Men and women =18 years of age, •Any patient eligible for transfemoral TAVI, irrespective of the chronic antithrombotic treatment, •Written informed consent, •Registered at the French social healthcare

排除标准

  • Any major protamine sulfate exposure contraindications defined as a history of severe pulmonary hypertension, acute pulmonary edema or history of bronchospasm related to protamine sulfate administration, •Pregnancy and breast feeding women, •Contemporaneous enrolment in an interventional clinical trial, •Patient under guardianship or curatorship, •Known allergy to protamine sulfate, •Hypersensitivity to protamine sulfate including protamine contained as an excipient in NPH [Neutral Protamine Hagedorn] insulin, known protamine or protamine-heparine complex antibodies, •Non-femoral approach for the TAVI procedure, •Protamine sulfate exposure within 24h of randomization, •Fish allergy, •Mechanical valves, •For men: Sterile or Vasectomy, •Women of childbearing potential

研究者

相似试验